STAR-GLOBAL 3-Year Results

Show Description +

I. Paul Singh, MD, shares an overview of data from the STAR-I, STAR-II, and STAR-III clinical trials for the MINIject (iSTAR Medical) MIGS device. He explains the patient population and parameters for these studies; outcomes from followup at 36 months including a 35.6% reduction in mean IOP; and how the device has helped patients lower IOP and reduce their medication burden. Dr. Singh also comments on further clinical trials currently underway.

Posted: 8/15/2023

Up Next

Q&A: MINIject Supraciliary MIGS Device

Steven R. Sarkisian Jr, MD; Karsten Klabe, MD; Faisal Ahmed, MD; and I. Paul Singh, MD


Full Webinar: An Eye-Opening Update on MIGS

Inder Paul Singh, MD, Iqbal Ike K. Ahmed, MD, FRCSC, Julián García-Feijoó, MD, PhD, Philippe Denis, MD, PhD

European STAR-II Trial Results at One Year

Julián García-Feijoó, MD, PhD

Webinar Part 1: Where Do We Stand With MIGS?

Iqbal Ike K. Ahmed, MD, FRCSC

Webinar Part 2: How Can We Leverage the Power of the Supraciliary Space?

Julián García-Feijoó, MD, PhD, Philippe Denis, MD, PhD, Inder Paul Singh, MD, Iqbal Ike K. Ahmed, MD, FRCSC

Webinar Part 3: The MINIject™ Next-Generation Supraciliary Device

Inder Paul Singh, MD, Iqbal Ike K. Ahmed, MD, FRCSC, Julián García-Feijoó, MD, PhD, Philippe Denis, MD, PhD

Webinar Part 6: Clinical Trial Results Q&A and Next Steps

Inder Paul Singh, MD, Iqbal Ike K. Ahmed, MD, FRCSC, Julián García-Feijoó, MD, PhD, Philippe Denis, MD, PhD

Enhanced and Sustained IOP reduction with MINIject

Iqbal Ike K. Ahmed, MD, FRCSC, Michel Vanbrabant, Steven Vold, MD

Consider the Supraciliary Space With MINIject

Joseph F. Panarelli, MD; and I. Paul Singh, MD

Question and Answer: MINIject Supraciliary MIGS Device

Joseph F. Panarelli, MD; Leon Au, BSc, MBBS, FRCOphth; and Tim Schultz, MD, PhD, FEBO

STAR-GLOBAL 3-Year Results

I. Paul Singh, MD, shares an overview of data from the STAR-I, STAR-II, and STAR-III clinical trials for the MINIject (iSTAR Medical) MIGS device. He explains the patient population and parameters for these studies; outcomes from followup at 36 months including a 35.6% reduction in mean IOP; and how the device has helped patients lower IOP and reduce their medication burden. Dr. Singh also comments on further clinical trials currently underway.

Posted: 8/15/2023

About iSTAR Medical

Visit us online: istarmed.com

Follow iSTAR Medical